{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:39:55Z","timestamp":1789756795219,"version":"4.0.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-022-08950-0","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T05:03:08Z","timestamp":1656651788000},"page":"19-30","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["The Treatment of Primary Immune Deficiencies: Lessons Learned and Future Opportunities"],"prefix":"10.1007","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2496-3947","authenticated-orcid":false,"given":"Kenneth","family":"Paris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke A.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,1]]},"reference":[{"issue":"3","key":"8950_CR1","first-page":"511","volume":"40","author":"D Chellapandian","year":"2020","unstructured":"Chellapandian D, Chitty-Lopez M, Leiding JW (2020) Precision therapy for the treatment of primary immunodysregulatory diseases. Immunology and Allergy Clinics 40(3):511\u2013526 (PMID: 32654696)","journal-title":"Immunology and Allergy Clinics"},{"key":"8950_CR2","doi-asserted-by":"crossref","unstructured":"Bousfiha A, Jeddane L, Picard C, Al-Herz W, Ailal F, Chatila T, Cunningham-Rundles C, Etzioni A, Franco JL, Holland SM, Klein C (2020) Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification. J Clin Immunol\u00a011:1\u20136. (PMID: 32048120; PMCID: PMC7082388)","DOI":"10.1007\/s10875-020-00758-x"},{"key":"8950_CR3","unstructured":"Invitae. Test Catalog: Primary Immunodeficiency Gene Panel. Retrieved May 8, 2022, from https:\/\/www.invitae.com\/en\/providers\/test-catalog\/test-08100"},{"issue":"5","key":"8950_CR4","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaci.2015.04.049","volume":"136","author":"FA Bonilla","year":"2015","unstructured":"Bonilla FA, Khan DA, Ballas ZK, Chinen J, Frank MM, Hsu JT, Keller M, Kobrynski LJ, Komarow HD, Mazer B, Nelson RP Jr (2015) Practice parameter for the diagnosis and management of primary immunodefieiency. Immunol Allergy Clin North Am 136(5):1186\u20131205","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"3","key":"8950_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jaci.2017.01.005","volume":"139","author":"MJ Dorsey","year":"2017","unstructured":"Dorsey MJ, Dvorak CC, Cowan MJ, Puck JM (2017) Treatment of infants identified as having severe combined immunodeficiency by means of newborn screening. J Allergy Clin Immunol 139(3):733\u2013742. https:\/\/doi.org\/10.1016\/j.jaci.2017.01.005 (PMID: 28270365; PMCID: PMC5385855)","journal-title":"J Allergy Clin Immunol"},{"key":"8950_CR6","doi-asserted-by":"publisher","unstructured":"Ballow M, Paris K, de la Morena M (2018) Should antibiotic prophylaxis be routinely used in patients with antibody-mediated primary immunodeficiency? J Allergy Clin Immunol Pract 6(2):421\u2013426. https:\/\/doi.org\/10.1016\/j.jaip.2017.11.024\u00a0(Epub 2017 Dec 21. PMID: 29274825)","DOI":"10.1016\/j.jaip.2017.11.024"},{"key":"8950_CR7","doi-asserted-by":"publisher","unstructured":"Eibl MM (2008) History of immunoglobulin replacement. Immunol Allergy Clin North Am 28(4):737\u201364, viii. https:\/\/doi.org\/10.1016\/j.iac.2008.06.004\u00a0(PMID: 18940572)","DOI":"10.1016\/j.iac.2008.06.004"},{"issue":"2612","key":"8950_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1126\/science.101.2612.51","volume":"101","author":"EJ Cohn","year":"1945","unstructured":"Cohn EJ (1945) Blood proteins and their therapeutic value. Science 101(2612):51\u201356. https:\/\/doi.org\/10.1126\/science.101.2612.51\u00a0(PMID: 17840912)","journal-title":"Science"},{"key":"8950_CR9","doi-asserted-by":"publisher","unstructured":"Cohn EJ, Luetscher JL, Oncley, SH et al (1940) Preparation and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibration across membranes with ethanol - water mixtures of controlled pH, ionic strength and temperature. J Am Chem Soc 62(12):3396\u20133400. https:\/\/doi.org\/10.1021\/ja01869a032","DOI":"10.1021\/ja01869a032"},{"key":"8950_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1423-0410.1962.tb03240.x","volume":"7","author":"S Barandun","year":"1962","unstructured":"Barandun S, Kistler P, Jeunet F, Isliker H (1962) Intravenous administration of human gamma-globulin. Vox Sang 7:157\u2013174 (PMID: 13864762)","journal-title":"Vox Sang"},{"issue":"6","key":"8950_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC (1952) Agammaglobulinemia. Pediatrics 9(6):722\u2013728 (PMID: 14929630)","journal-title":"Agammaglobulinemia Pediatrics"},{"key":"8950_CR12","unstructured":"MRC Working Party on Hypogammaglobuinaemia. Hypogammaglobulinaemia in the UK. London"},{"issue":"8205","key":"8950_CR13","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/S0140-6736(80)92594-5","volume":"2","author":"HD Ochs","year":"1980","unstructured":"Ochs HD, Buckley RH, Pirofsky B, Fischer SH, Rousell RH, Anderson CJ, Wedgwood RJ (1980) Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet 2(8205):1158\u20131159 (PMID: 6107768)","journal-title":"Lancet"},{"key":"8950_CR14","unstructured":"Centers for Disease Control and Prevention (CDC) (1999) Renal insufficiency and failure associated with immune globulin intravenous therapy - United States, 1985\u20131998. Morb Mortal Wkly Rep 48(24):518\u201321 (PMID: 10401909)"},{"issue":"1","key":"8950_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.iac.2018.08.001","volume":"39","author":"RL Wasserman","year":"2019","unstructured":"Wasserman RL (2019) Personalized therapy: immunoglobulin replacement for antibody deficiency. Immunol Allergy Clin North Am 39(1):95\u2013111. https:\/\/doi.org\/10.1016\/j.iac.2018.08.001 (PMID: 30466775)","journal-title":"Immunol Allergy Clin North Am"},{"issue":"10","key":"8950_CR16","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1111\/trf.12663","volume":"54","author":"G Sridhar","year":"2014","unstructured":"Sridhar G, Ekezue BF, Izurieta HS, Selvam N, Ovanesov MV, Divan HA, Liang Y, Golding B, Forshee RA, Anderson SA, Menis M (2014) Immune globulins and same-day thrombotic events as recorded in a large health care database during 2008\u20132012. Transfusion 54(10):2553\u20132565 (PMID: 24804899)","journal-title":"Transfusion"},{"key":"8950_CR17","doi-asserted-by":"publisher","unstructured":"Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M (2006) Subcutaneous IgG Study Group. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 26(3):265\u201373. https:\/\/doi.org\/10.1007\/s10875-006-9021-7\u00a0(PMID: 16783465)","DOI":"10.1007\/s10875-006-9021-7"},{"key":"8950_CR18","doi-asserted-by":"publisher","unstructured":"Wasserman RL, Melamed I, Stein MR, Gupta S, Puck J, Engl W, Leibl H, McCoy B, Empson VG, Gelmont D, Schiff RI; IGSC, 10% with rHuPH20 study group. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol. 2012 Oct;130(4):951\u20137.e11. https:\/\/doi.org\/10.1016\/j.jaci.2012.06.021\u00a0(Epub 2012 Jul 28. PMID: 22846381)","DOI":"10.1016\/j.jaci.2012.06.021"},{"key":"8950_CR19","unstructured":"IG Therapy Products and Risk Factor Chart (2022) Immunoglobulin National Society. May 2, 2022, from https:\/\/ig-ns.org\/product\/ig-therapy-products-and-risk-factor-chart\/"},{"issue":"1","key":"8950_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clim.2010.06.012","volume":"137","author":"JS Orange","year":"2010","unstructured":"Orange JS, Grossman WJ, Navickis RJ, Wilkes MM (2010) Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 137(1):21\u201330. https:\/\/doi.org\/10.1016\/j.clim.2010.06.012 (Epub 2010 Aug 1. PMID: 20675197)","journal-title":"Clin Immunol"},{"issue":"1","key":"8950_CR21","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.jaci.2008.04.044","volume":"122","author":"VR Bonagura","year":"2008","unstructured":"Bonagura VR, Marchlewski R, Cox A, Rosenthal DW (2008) Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 122(1):210\u2013212. https:\/\/doi.org\/10.1016\/j.jaci.2008.04.044 (PMID: 18602574)","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"8950_CR22","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jaci.2004.10.012","volume":"115","author":"K Chan","year":"2005","unstructured":"Chan K, Puck JM (2005) Development of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 115(2):391\u2013398. https:\/\/doi.org\/10.1016\/j.jaci.2004.10.012 (PMID: 15696101)","journal-title":"J Allergy Clin Immunol"},{"key":"8950_CR23","doi-asserted-by":"publisher","unstructured":"Buckley RH (2012) The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol 129(3):597\u2013604; quiz 605\u20136. https:\/\/doi.org\/10.1016\/j.jaci.2011.12.964\u00a0(Epub 2012 Jan 24. PMID: 22277203; PMCID: PMC3294102)","DOI":"10.1016\/j.jaci.2011.12.964"},{"issue":"1","key":"8950_CR24","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/imr.12729","volume":"287","author":"JM Puck","year":"2019","unstructured":"Puck JM (2019) Newborn screening for severe combined immunodeficiency and T-cell lymphopenia. Immunol Rev 287(1):241\u2013252. https:\/\/doi.org\/10.1111\/imr.12729 (PMID: 30565242; PMCID: PMC6324582)","journal-title":"Immunol Rev"},{"issue":"7","key":"8950_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jama.2014.9132.Erratum.In:JAMA.2014Nov26;312(20):2169.Bonagura,VincentR[Added]","volume":"312","author":"A Kwan","year":"2014","unstructured":"Kwan A, Abraham RS, Currier R et al (2014) Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA 312(7):729\u2013738. https:\/\/doi.org\/10.1001\/jama.2014.9132.Erratum.In:JAMA.2014Nov26;312(20):2169.Bonagura,VincentR[Added] (PMID: 25138334; PMCID: PMC4492158)","journal-title":"JAMA"},{"issue":"7583","key":"8950_CR26","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/s0140-6736(68)92673-1","volume":"2","author":"RA Gatti","year":"1968","unstructured":"Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA (1968) Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 2(7583):1366\u20131369. https:\/\/doi.org\/10.1016\/s0140-6736(68)92673-1 (PMID: 4177932)","journal-title":"Lancet"},{"issue":"5","key":"8950_CR27","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1056\/NEJMoa1401177","volume":"371","author":"SY Pai","year":"2014","unstructured":"Pai SY, Logan BR, Griffith LM, Buckley RH et al (2014) Transplantation outcomes for severe combined immunodeficiency, 2000\u20132009. N Engl J Med 371(5):434\u2013446. https:\/\/doi.org\/10.1056\/NEJMoa1401177 (PMID: 25075835; PMCID: PMC4183064)","journal-title":"N Engl J Med"},{"key":"8950_CR28","doi-asserted-by":"publisher","unstructured":"Gennery AR, Slatter MA, Grandin L, Taupin P, Cant AJ et al (2010) Inborn errors working party of the european group for blood and marrow transplantation; european society for immunodeficiency. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol 126(3):602\u201310.e1\u201311. https:\/\/doi.org\/10.1016\/j.jaci.2010.06.015\u00a0(Epub 2010 Jul 31. PMID: 20673987)","DOI":"10.1016\/j.jaci.2010.06.015"},{"key":"8950_CR29","doi-asserted-by":"publisher","unstructured":"Fernandes JF, Rocha V, Labopin M, Neven B, Moshous D, Gennery AR et al (2012) Eurocord and inborn errors working party of european group for blood and marrow transplantation. Transplantation in patients with SCID: mismatched related stem cells or unrelated cord blood? Blood\u00a0119(12):2949\u201355.\u00a0https:\/\/doi.org\/10.1182\/blood-2011-06-363572\u00a0(Epub 2012 Feb 3. PMID: 22308292)","DOI":"10.1182\/blood-2011-06-363572"},{"issue":"10","key":"8950_CR30","first-page":"3646","volume":"91","author":"E Haddad","year":"1998","unstructured":"Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, Morgan G, Bertrand Y, Fasth A, Porta F, Cant A, Espanol T, M\u00fcller S, Veys P, Vossen J, Fischer A (1998) Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood 91(10):3646\u20133653 (PMID: 9573000)","journal-title":"Blood"},{"issue":"2","key":"8950_CR31","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1182\/blood-2004-03-0960","volume":"105","author":"K Rao","year":"2005","unstructured":"Rao K, Amrolia PJ, Jones A, Cale CM, Naik P, King D, Davies GE, Gaspar HB, Veys PA (2005) Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 105(2):879\u2013885. https:\/\/doi.org\/10.1182\/blood-2004-03-0960 (Epub 2004 Sep 14. PMID: 15367433)","journal-title":"Blood"},{"issue":"5","key":"8950_CR32","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jaci.2013.05.031","volume":"132","author":"T Cole","year":"2013","unstructured":"Cole T, Pearce MS, Cant AJ, Cale CM, Goldblatt D, Gennery AR (2013) Clinical outcome in children with chronic granulomatous disease managed conservatively or with hematopoietic stem cell transplantation. J Allergy Clin Immunol 132(5):1150\u20131155 (Epub 2013 Jul 16. PMID: 23870668)","journal-title":"J Allergy Clin Immunol"},{"key":"8950_CR33","doi-asserted-by":"publisher","unstructured":"G\u00fcng\u00f6r T, Teira P, Slatter M, Stussi G, Stepensky P, Moshous D et al (2014) Inborn Errors Working Party of the European Society for Blood and Marrow Transplantation. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet\u00a0383(9915):436\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(13)62069-3\u00a0(Epub 2013 Oct 23. PMID: 24161820)","DOI":"10.1016\/S0140-6736(13)62069-3"},{"issue":"1","key":"8950_CR34","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/hematology.2019000052","volume":"2019","author":"SY Pai","year":"2019","unstructured":"Pai SY (2019) Treatment of primary immunodeficiency with allogeneic transplant and gene therapy. Hematology Am Soc Hematol Educ Program 2019(1):457\u2013465. https:\/\/doi.org\/10.1182\/hematology.2019000052 (PMID: 31808905; PMCID: PMC6913427)","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"8950_CR35","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/87687","volume":"2","author":"JM Penninger","year":"2001","unstructured":"Penninger JM, Iriel-Sasaki J, Sasaki T, Oliveira-dos-Santos AJ (2001) CD45: new jobs for an old acquaintance. Nat Immunol 2(5):389\u2013396 (PMID: 11323691)","journal-title":"Nat Immunol"},{"issue":"1","key":"8950_CR36","first-page":"113","volume":"39","author":"O Shamriz","year":"2019","unstructured":"Shamriz O, Chandrakasan S (2019) Update on advances in hematopoietic cell transplantation for primary immunodeficiency disorders. Immunology and Allergy Clinics 39(1):113\u2013128 (PMID: 30466768)","journal-title":"Immunology and Allergy Clinics"},{"issue":"5","key":"8950_CR37","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","volume":"124","author":"A Bertaina","year":"2014","unstructured":"Bertaina A, Merli P, Rutella S, Pagliara D, Bernardo ME, Masetti R, Pende D, Falco M, Handgretinger R, Moretta F, Lucarelli B (2014) HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders. Blood 124(5):822\u2013826 (PMID: 24869942)","journal-title":"Blood"},{"key":"8950_CR38","doi-asserted-by":"crossref","unstructured":"Naik S, Nicholas SK, Martinez CA, Leen AM, Hanley PJ, Gottschalk SM, Rooney CM, Hanson IC, Krance RA, Shpall EJ, Cruz CR (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137(5):1498\u2013505. (PMID: 26920464; PMCID: PMC4860050)","DOI":"10.1016\/j.jaci.2015.12.1311"},{"key":"8950_CR39","doi-asserted-by":"publisher","unstructured":"Fox TA, Booth C (2020) Gene therapy for primary immunodeficiencies. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.17269\u00a0(Epub ahead of print. PMID: 33336808)","DOI":"10.1111\/bjh.17269"},{"issue":"6","key":"8950_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/00130832-200312000-00007","volume":"3","author":"A Aiuti","year":"2003","unstructured":"Aiuti A, Ficara F, Cattaneo F, Bordignon C, Roncarolo MG (2003) Gene therapy for adenosine deaminase deficiency. Curr Opin Allergy Clin Immunol 3(6):461\u2013466. https:\/\/doi.org\/10.1097\/00130832-200312000-00007 (PMID: 14612670)","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"7","key":"8950_CR41","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nm0798-775","volume":"4","author":"DB Kohn","year":"1998","unstructured":"Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J et al (1998) T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 4(7):775\u2013780. https:\/\/doi.org\/10.1038\/nm0798-775 (PMID:9662367; PMCID: PMC3777239)","journal-title":"Nat Med"},{"issue":"6","key":"8950_CR42","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15252\/emmm.201707573","volume":"9","author":"A Aiuti","year":"2017","unstructured":"Aiuti A, Roncarolo MG, Naldini L (2017) Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products. EMBO Mol Med 9(6):737\u2013740. https:\/\/doi.org\/10.15252\/emmm.201707573 (PMID:28396566; PMCID: PMC5452047)","journal-title":"EMBO Mol Med"},{"issue":"16","key":"8950_CR43","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","volume":"380","author":"E Mamcarz","year":"2019","unstructured":"Mamcarz E, Zhou S, Lockey T, Abdelsamed H, Cross SJ, Kang G et al (2019) Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1. N Engl J Med 380(16):1525\u20131534. https:\/\/doi.org\/10.1056\/NEJMoa1815408 (PMID: 30995372; PMCID: PMC6636624)","journal-title":"N Engl J Med"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-022-08950-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-022-08950-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:49:25Z","timestamp":1744188565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-022-08950-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["8950"],"URL":"https:\/\/doi.org\/10.1007\/s12016-022-08950-0","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]},"assertion":[{"value":"31 May 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable\/no human subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable\/no human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"Kenneth Paris MD: Dr. Paris has been a member of advisory boards and a speaker for Takeda Pharmaceuticals regarding the treatment and diagnosis of primary immunodeficiency. He has participated in clinical trials with Takeda regarding immunoglobulin products and with Chiesi Pharmaceuticals regarding enzyme replacement for ADA-SCID. He is also on the Medical Advisory Committee for the Immunoglobulin National Society who provided figures for this manuscript.\u00a0Luke Wall MD: Dr. Wall has participated in clinical trials with Takeda Pharmaceuticals regarding immunoglobulin products, and with Chiesi Pharmaceuticals regarding enzyme replacement for ADA-SCID.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}